

# Vasileios Askoxylakis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3637909/publications.pdf>

Version: 2024-02-01

17  
papers

1,488  
citations

840776

11  
h-index

1199594

12  
g-index

17  
all docs

17  
docs citations

17  
times ranked

3003  
citing authors

#	ARTICLE	IF	CITATIONS
1	BSCI-10. NEUROLOGICAL DYSFUNCTION CAUSED BY BRAIN TUMOR-GENERATED SOLID STRESS IS REVERSED BY LITHIUM. <i>Neuro-Oncology Advances</i> , 2019, 1, i2-i3.	0.7	0
2	Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer. <i>Scientific Reports</i> , 2019, 9, 16832.	3.3	13
3	BSCI-09. MECHANISMS OF ENHANCED DRUG DELIVERY IN BRAIN METASTASES WITH FOCUSED ULTRASOUND-INDUCED BLOOD-TUMOR BARRIER DISRUPTION. <i>Neuro-Oncology Advances</i> , 2019, 1, i2-i2.	0.7	0
4	Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithium. <i>Nature Biomedical Engineering</i> , 2019, 3, 230-245.	22.5	127
5	Dual endothelin receptor inhibition enhances T-DM1 efficacy in brain metastases from HER2-positive breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 4.	5.2	12
6	Shortwave infrared fluorescence imaging with the clinically approved near-infrared dye indocyanine green. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 4465-4470.	7.1	498
7	CADD-32. MECHANISMS OF ENHANCED DRUG DELIVERY IN BRAIN TUMORS WITH FOCUSED ULTRASOUND-INDUCED TRANSIENT BLOOD-TUMOR BARRIER DISRUPTION. <i>Neuro-Oncology</i> , 2018, 20, vi281-vi281.	1.2	0
8	Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood-tumor barrier disruption. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E8717-E8726.	7.1	159
9	Solid stress and elastic energy as measures of tumour mechanopathology. <i>Nature Biomedical Engineering</i> , 2017, 1, .	22.5	280
10	Emerging strategies for delivering antiangiogenic therapies to primary and metastatic brain tumors. <i>Advanced Drug Delivery Reviews</i> , 2017, 119, 159-174.	13.7	25
11	The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	89
12	Notice of Removal: Evaluation of anticancer agent transport in brain tumors after focused ultrasound-induced blood-brain/blood-tumor barrier disruption. , 2017, , .		0
13	Antibody-based therapies for the treatment of brain metastases from HER2-positive breast cancer: time to rethink the importance of the BBB?. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 467-468.	2.5	4
14	IMST-40. REPROGRAMMING OF THE TUMOR IMMUNE MICROENVIRONMENT BY AN ANG-2/VEGF BISPECIFIC ANTIBODY DELAYS TUMOR GROWTH AND PROLONGS SURVIVAL IN PRECLINICAL GBM MODELS. <i>Neuro-Oncology</i> , 2016, 18, vi95-vi95.	1.2	0
15	Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	6.3	56
16	Emerging Strategies for Treating Brain Metastases from Breast Cancer. <i>Cancer Cell</i> , 2015, 27, 163-175.	16.8	119
17	Blockade of MMP14 Activity in Murine Breast Carcinomas: Implications for Macrophages, Vessels, and Radiotherapy. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	106